182 related articles for article (PubMed ID: 21209397)
41. Comparative efficacy and safety of low-dose pitavastatin versus atorvastatin in patients with hypercholesterolemia.
Sansanayudh N; Wongwiwatthananukit S; Putwai P; Dhumma-Upakorn R
Ann Pharmacother; 2010 Mar; 44(3):415-23. PubMed ID: 20179259
[TBL] [Abstract][Full Text] [Related]
42. Chemoprevention of arylamine-induced colorectal aberrant crypts.
Feng Y; Neale JR; Doll MA; Hein DW
Exp Biol Med (Maywood); 2008 Jan; 233(1):71-5. PubMed ID: 18156308
[TBL] [Abstract][Full Text] [Related]
43. The atorvastatin during ischemic stroke study: a pilot randomized controlled trial.
Muscari A; Puddu GM; Santoro N; Serafini C; Cenni A; Rossi V; Zoli M
Clin Neuropharmacol; 2011; 34(4):141-7. PubMed ID: 21677574
[TBL] [Abstract][Full Text] [Related]
44. Effects of intervention with sulindac and inulin/VSL#3 on mucosal and luminal factors in the pouch of patients with familial adenomatous polyposis.
Friederich P; Verschuur J; van Heumen BW; Roelofs HM; Berkhout M; Nagtegaal ID; van Oijen MG; van Krieken JH; Peters WH; Nagengast FM
Int J Colorectal Dis; 2011 May; 26(5):575-82. PubMed ID: 21243500
[TBL] [Abstract][Full Text] [Related]
45. Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial--FAT).
Malik J; Melenovsky V; Wichterle D; Haas T; Simek J; Ceska R; Hradec J
Cardiovasc Res; 2001 Nov; 52(2):290-8. PubMed ID: 11684077
[TBL] [Abstract][Full Text] [Related]
46. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.
Sever PS; Dahlöf B; Poulter NR; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J;
Drugs; 2004; 64 Suppl 2():43-60. PubMed ID: 15765890
[TBL] [Abstract][Full Text] [Related]
47. Intestinal cholesterol absorption, treatment with atorvastatin, and cardiovascular risk in hemodialysis patients.
Silbernagel G; Fauler G; Genser B; Drechsler C; Krane V; Scharnagl H; Grammer TB; Baumgartner I; Ritz E; Wanner C; März W
J Am Coll Cardiol; 2015 Jun; 65(21):2291-8. PubMed ID: 26022817
[TBL] [Abstract][Full Text] [Related]
48. The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K.
Sever PS; Chang CL; Gupta AK; Whitehouse A; Poulter NR;
Eur Heart J; 2011 Oct; 32(20):2525-32. PubMed ID: 21873710
[TBL] [Abstract][Full Text] [Related]
49. Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial.
Bone HG; Kiel DP; Lindsay RS; Lewiecki EM; Bolognese MA; Leary ET; Lowe W; McClung MR
J Clin Endocrinol Metab; 2007 Dec; 92(12):4671-7. PubMed ID: 17726081
[TBL] [Abstract][Full Text] [Related]
50. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
Yee HS; Fong NT
Ann Pharmacother; 1998 Oct; 32(10):1030-43. PubMed ID: 9793596
[TBL] [Abstract][Full Text] [Related]
51. A randomized placebo controlled trial of early treatment of acute ischemic stroke with atorvastatin and irbesartan.
Beer C; Blacker D; Bynevelt M; Hankey GJ; Puddey IB
Int J Stroke; 2012 Feb; 7(2):104-11. PubMed ID: 22044557
[TBL] [Abstract][Full Text] [Related]
52. Interaction between a commercially available St. John's wort product (Movina) and atorvastatin in patients with hypercholesterolemia.
Andrén L; Andreasson A; Eggertsen R
Eur J Clin Pharmacol; 2007 Oct; 63(10):913-6. PubMed ID: 17701167
[TBL] [Abstract][Full Text] [Related]
53. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.
Bakker-Arkema RG; Davidson MH; Goldstein RJ; Davignon J; Isaacsohn JL; Weiss SR; Keilson LM; Brown WV; Miller VT; Shurzinske LJ; Black DM
JAMA; 1996 Jan; 275(2):128-33. PubMed ID: 8531308
[TBL] [Abstract][Full Text] [Related]
54. Chemoprevention for colorectal tumorigenesis associated with chronic colitis in mice via apoptosis.
Orii S; Yamaguchi T; Anzai H; Saito S; Chiba T; Suzuki K
J Exp Clin Cancer Res; 2003 Mar; 22(1):41-6. PubMed ID: 12725321
[TBL] [Abstract][Full Text] [Related]
55. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.
Wanner C; Krane V; März W; Olschewski M; Mann JF; Ruf G; Ritz E;
N Engl J Med; 2005 Jul; 353(3):238-48. PubMed ID: 16034009
[TBL] [Abstract][Full Text] [Related]
56. Chemoprevention of colorectal cancer.
Niitsu Y; Takayama T; Miyanishi K; Nobuoka A; Hayashi T; Kukitsu T; Takanashi K; Ishiwatari H; Abe T; Kogawa T; Takahashi M; Matsunaga T; Kato J
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S40-3. PubMed ID: 15309513
[TBL] [Abstract][Full Text] [Related]
57. The effect of wheat bran fiber and calcium supplementation on rectal mucosal proliferation rates in patients with resected adenomatous colorectal polyps.
Alberts DS; Einspahr J; Ritenbaugh C; Aickin M; Rees-McGee S; Atwood J; Emerson S; Mason-Liddil N; Bettinger L; Patel J; Bellapravalu S; Ramanujam PS; Phelps J; Clark L
Cancer Epidemiol Biomarkers Prev; 1997 Mar; 6(3):161-9. PubMed ID: 9138658
[TBL] [Abstract][Full Text] [Related]
58. Atorvastatin: its clinical role in cerebrovascular prevention.
Gaspardone A; Arca M
Drugs; 2007; 67 Suppl 1():55-62. PubMed ID: 17910521
[TBL] [Abstract][Full Text] [Related]
59. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
Jones PH; Davidson MH; Stein EA; Bays HE; McKenney JM; Miller E; Cain VA; Blasetto JW;
Am J Cardiol; 2003 Jul; 92(2):152-60. PubMed ID: 12860216
[TBL] [Abstract][Full Text] [Related]
60. Atorvastatin induces apoptosis in vitro and slows growth of tumor xenografts but not polyp formation in MIN mice.
Huang EH; Johnson LA; Eaton K; Hynes MJ; Carpentino JE; Higgins PD
Dig Dis Sci; 2010 Nov; 55(11):3086-94. PubMed ID: 20186482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
